|
Hospitalization rates |
||||||
| Children ≤ 2 years old with BPD/CLD (n = 3675) |
Infants at gestational age 29–32 weeks without CLD (n = 4854) |
Infants at gestational age 32–35 weeks without CLD (n = 2829) |
||||
|
|
|
|
||||
| Reference (country) |
Untreated |
Palivizumab |
Untreated |
Palivizumab |
Untreated |
Palivizumab |
|
|
||||||
| [23] (USA) |
36.7% (30) |
- |
- |
- |
- |
- |
| [24] (USA) |
17.4% (149) |
- |
- |
- |
- |
- |
| [52] (USA) |
25.2% (131) |
- |
7.6% (662) |
- |
- |
- |
| [53] (UK) |
19.1% (235) |
- |
- |
- |
- |
- |
| [32] (USA/Can/UK) |
12.8% (266) |
7.9% (496) |
8.5% (142) |
1.6% (313) |
9.8% (123) |
2.0% (250) |
| [35] (USA; outcomes 1998–1999) |
- |
4.0% (402) |
- |
2.0% (506) |
- |
1.5% (548) |
| [36] (USA; outcomes 1999–2000) |
- |
3.9% (795) |
- |
2.3% (690) |
- |
1.3% (972) |
| [39] (Canada) |
- |
6.0% (95) |
- |
1.3% (199) |
- |
- |
| [40] (The Netherlands) |
- |
3.4% (88) |
- |
0.8% (124) |
- |
- |
| Unpublished data (France) |
- |
7.6% (506) |
- |
- |
- |
- |
| [37] (USA; registry 2000–2001) |
- |
5.8% (482) |
- |
2.3% (650) |
- |
1.6% (936) |
| [54] (Spain) |
- |
- |
10.1% (456) |
- |
- |
- |
| [55] (Spain) |
- |
- |
12.9% (827) |
- |
- |
- |
| [41] (international study) |
- |
- |
- |
2.1% (285) |
- |
- |
| Weighted mean rate |
18.4% (811) |
5.6% (2864) |
10.3% (2087) |
2.0% (2767) |
9.8% (123) |
1.5% (2706) |
|
Values are expressed as % (n). Hospitalization rates due to respiratory syncytial virus (RSV) in children ≤ 2 years old with bronchopulmonary dysplasia (BPD)/chronic lung disease (CLD), infants at gestational age 29–32 weeks without CLD, and infants at gestational age 32–35 weeks without CLD (combined analysis). -, not studied. Adapted from Simoes [44]. | ||||||
Simoes Respiratory Research 2002 3(Suppl 1):S26 doi:10.1186/rr187 |
||||||